Clinical Research Directory
Browse clinical research sites, groups, and studies.
Open Label Phase IIa Trial Evaluating the Effect and Safety of Transplantation of Fecal Microbiota in Children With Autism Spectrum Disorders and Gastrointestinal Symptoms
Sponsor: Assistance Publique - Hôpitaux de Paris
Summary
Autism Spectrum Disorders (ASD), affect approximately 1% of the general population and are characterized by impairments in social communication associated with repetitive/stereotyped behaviors. Approximately one-third of these patients display gastrointestinal (GI) symptoms, and a growing number of studies suggest abnormalities of gut microbiota in ASD. Gut microbiota and the brain interact through complex pathways. Preliminary evidence in adults with ASD suggests that modulation of the gut microbiota by probiotics and/or prebiotics and more recently by fecal microbiota transplantation could improve GI symptoms but also socio-communication deficit, with persistent improvement at year 2.
Official title: A Proof of Concept Study : Open Label Phase IIa Trial Evaluating the Effect and Safety of Transplantation of Fecal Microbiota in Children With Autism Spectrum Disorders and Gastrointestinal Symptoms
Key Details
Gender
All
Age Range
36 Months - 72 Months
Study Type
INTERVENTIONAL
Enrollment
5
Start Date
2025-09-01
Completion Date
2027-04-01
Last Updated
2025-08-05
Healthy Volunteers
No
Interventions
FMT Protocol
FMT protocol Samples (urine, blood, stool) collection Psychological examination Pediatric quality of life Scale Bristol Stool form Scale
Locations (1)
Robert Debré Hospital
Paris, Ap-hp / DRCI, France